JP2012506429A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506429A5
JP2012506429A5 JP2011533151A JP2011533151A JP2012506429A5 JP 2012506429 A5 JP2012506429 A5 JP 2012506429A5 JP 2011533151 A JP2011533151 A JP 2011533151A JP 2011533151 A JP2011533151 A JP 2011533151A JP 2012506429 A5 JP2012506429 A5 JP 2012506429A5
Authority
JP
Japan
Prior art keywords
magnesium
sequelae
lipoate
insulin resistance
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011533151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/081128 external-priority patent/WO2010047717A1/en
Publication of JP2012506429A publication Critical patent/JP2012506429A/ja
Publication of JP2012506429A5 publication Critical patent/JP2012506429A5/ja
Pending legal-status Critical Current

Links

JP2011533151A 2008-10-24 2008-10-24 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩 Pending JP2012506429A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/081128 WO2010047717A1 (en) 2008-10-24 2008-10-24 Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities

Publications (2)

Publication Number Publication Date
JP2012506429A JP2012506429A (ja) 2012-03-15
JP2012506429A5 true JP2012506429A5 (OSRAM) 2012-05-17

Family

ID=42119567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533151A Pending JP2012506429A (ja) 2008-10-24 2008-10-24 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩

Country Status (5)

Country Link
US (2) US8222432B2 (OSRAM)
EP (1) EP2349322A4 (OSRAM)
JP (1) JP2012506429A (OSRAM)
CA (1) CA2741700A1 (OSRAM)
WO (1) WO2010047717A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US8597264B2 (en) 2011-03-24 2013-12-03 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
EP2976095B1 (en) 2013-03-15 2020-12-23 3M Innovative Properties Company Wound healing compositions
US20200383946A1 (en) * 2019-05-07 2020-12-10 Aciont Inc. Lipoic acid formulations
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法
CN116041318B (zh) * 2022-12-29 2025-04-18 江苏恒沛药物科技有限公司 一种制备硫辛酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115589T3 (es) * 1989-11-09 1998-07-01 Asta Medica Ag Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
US5349100A (en) * 1991-01-02 1994-09-20 Exxon Chemical Patents Inc. Chiral metallocene compounds and preparation thereof by creation of a chiral center by enantioselective hydride transfer
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6524619B2 (en) * 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
IT1319195B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US7030154B2 (en) * 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
CN1896072A (zh) * 2005-07-16 2007-01-17 南京莱尔生物化工有限公司 R－硫辛酸及其盐的制备方法
JP2009541220A (ja) * 2006-06-16 2009-11-26 インディジーン ファーマシューティカルズ インコーポレイテッド 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート
US8324191B2 (en) * 2008-07-11 2012-12-04 Biolink Life Sciences, Inc Combined calcium, magnesium and vitamin D supplements
US8080674B2 (en) * 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt

Similar Documents

Publication Publication Date Title
JP2012506429A5 (OSRAM)
JP2013525444A5 (OSRAM)
SI2498801T1 (en) A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
JP2008540394A5 (OSRAM)
NZ807894A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2015132860A (ru) Композиции инсулинов длительного действия
EP3192506A3 (en) Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient
JP2012520343A5 (OSRAM)
JP2010514831A5 (OSRAM)
JP6401317B2 (ja) がんを治療するためのシステム、方法、および製剤
IL314360B1 (en) Method for the synthesis of thyroid hormone analogs and their polymorphs
JP2012520343A (ja) 代謝障害治療のための併用療法
JP2015503593A5 (OSRAM)
JP2015143248A5 (OSRAM)
HRP20240034T1 (hr) Liječenje kardiovaskularnih bolesti
MY174002A (en) Combination theraphy for the treatment of diabetes
JP2012523395A5 (OSRAM)
JP2013541583A5 (OSRAM)
WO2008030830A3 (en) Sustained-release composition and method of use thereof
JP2012533559A5 (OSRAM)
JP2011046708A5 (OSRAM)
EA021395B1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
ES2763437T3 (es) Composición para el tratamiento de la esterilidad
JP2017528473A5 (OSRAM)
RU2014148977A (ru) Обработка популяции рыб луфенуроном